中生制药：正大天晴与阿斯利康就TQC3721签独家授权协议
2026-07-08 02:22:12
据明报报道，中生制药(1177)公布，集团附属公司正大天晴已与阿斯利康就集团自主研发的PDE3/4抑制剂（研发代号：TQC3721）订立独家授权协议。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
ArkStream Capital Partner Ye Su Says Firm Passed on Li Bojie Project After Due DiligenceNext article：
股票市场 | 元大证券：LG电子盈利或复苏
